1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

T2 Biosystems Executes Territory Exclusive Distribution Agreement in Malaysia & Indonesia

01 Aug 2024
Admin
News Article

T2 Biosystems Executes Territory Exclusive Distribution Agreement in Malaysia & Indonesia

Overview

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, announced the execution of a territory exclusive distribution agreement in Malaysia and Indonesia.

Terms of the Agreement

Under the terms of the agreement, T2 Biosystems will sell the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, and the T2Resistance Panel through the newly appointed distributor.

Statement from the CEO: T2 Biosystems

This distribution agreement represents continued momentum in our international commercial expansion efforts and, together with our recently announced expansion into Hong Kong and Macau, marks four new territories entered into Asia Pacific in the past month,” stated John Sperzel, chairman and CEO of T2 Biosystems.
Improving the quality of care for patients at risk of sepsis is a critical global health initiative and we are proud to offer a solution to advance patient care by supplying our culture-independent diagnostics to our distributor partners in Malaysia and Indonesia. We are excited to grow with our new partners as we form long-lasting relationships.

T2 Biosystem in Asia Pacific region

The execution of this exclusive distribution agreement further expands T2 Biosystems’ commercialization in the Asia Pacific region.
A study from Malaysia found that sepsis was the most common diagnosis leading to intensive care unit (ICU) admission and the in-hospital mortality rate in the ICU for sepsis was over 50%.
In Indonesia, a study from a tertiary care hospital found that 18.5% of patients admitted to the hospital had sepsis and patients admitted to the intensive care unit with sepsis had a mortality rate of 68%.
The introduction of the T2Dx Instrument and sepsis test panels into Malaysia and Indonesia will allow rapid detection of certain sepsis-causing pathogens and antibiotic resistance genes, in hours instead of days, enabling clinicians to achieve targeted therapy, faster.

About T2 Biosystems

T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before.